United States · FDA National Drug Code directory
Tecentriq Hybreza
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 50242-933_87c7ca7b-0b4e-456a-8338-80c9613edb36
- Product NDC
- 50242-933
- Form
- INJECTION
- Composition / generic term
- atezolizumab and hyaluronidase-tqjs
- Labeler
- Genentech, Inc.
- Marketing category
- BLA
- Marketing start / end (source format)
- 20240912
- Source listing expiry
- 20271231
Source-listed ingredients
- ATEZOLIZUMAB — 1875 mg/15mL
- HYALURONIDASE (HUMAN RECOMBINANT) — 30000 U/15mL
These values do not establish equivalence or a dose recommendation.
Packages
- 1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-01) / 15 mL in 1 VIAL, SINGLE-DOSE · 50242-933-01
- 1 VIAL, SINGLE-DOSE in 1 BOX (50242-933-86) / 15 mL in 1 VIAL, SINGLE-DOSE · 50242-933-86
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →